Leerink analyst Andrew Berens downgraded Compass Therapeutics (CMPX) to Market Perform from Outperform with a price target of $4, down from $5. The firm sees a “number of uncertainties in key value drivers for the company.” The analyst removed the third-line colorectal cancer monotherapy and gastric cancer opportunities for CTX-009 due to lack of commitment to these settings.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics Reports Q3 2024 Financials and Clinical Progress
- Compass Therapeutics price target raised to $7 from $5 at Ladenburg
- Compass Therapeutics reports Q3 EPS (8c), consensus (11c)
- Compass Therapeutics sees cash runway into 1Q27
- Compass Therapeutics presents biomarker data related to CTX-471